Cann Group: Receives UK FSA approval for Satipharm CBD products

Cann Group Receives UK FSA approval for Satipharm CBD products

• Cann Group (CAN) gets the tick of approval from the UK Foods Standards Agency (FSA) for its Satipharm range of CBD products
• The company said this is a “major opportunity” as it allows its CBD products to be sold in the UK
• This news marks a milestone for the UK CBD industry and removes any uncertainty within the supply chain around CBD products
• The capsules are clinically proven to deliver around 3.5 times higher total bioavailability compared to standard CBD oil
• On the market, Cann shares were up 7.84 per cent and trading at 27.5 cents per share